1. The Impact of the COVID-19 Pandemic on Adherence to Endocrine Therapy for Breast Cancer in Catalonia (Spain).
- Author
-
Navarro-Sabate, Aurea, Font, Rebeca, Martínez-Soler, Fina, Solà, Judit, Tortosa, Avelina, Ribes, Josepa, Benito-Aracil, Llúcia, Espinas, Josep Alfons, and Borras, Josep Maria
- Subjects
- *
BREAST tumor treatment , *THERAPEUTIC use of antineoplastic agents , *ORAL drug administration , *MULTIPLE regression analysis , *AGE distribution , *RETROSPECTIVE studies , *ANTINEOPLASTIC agents , *DRUGS , *CHI-squared test , *DESCRIPTIVE statistics , *RESEARCH funding , *PATIENT compliance , *TAMOXIFEN , *COMBINED modality therapy , *COVID-19 pandemic , *LONGITUDINAL method - Abstract
Simple Summary: Oral endocrine therapy is a key component of breast cancer treatment in hormone-positive patients, the most frequent subtype of this cancer. Adherence to this treatment is a factor related to an increased probability of relapse and death. The COVID-19 pandemic has had a disruptive impact on the use of cancer services, delaying diagnosis and stopping screening during the peak of the pandemic. We assessed the impact of the COVID-19 on the adherence to oral endocrine therapy in Catalonia (Spain) using the data collected in the clinical records of the public health care system. We have found that the first wave of the COVID-19 (between March and September 2020) was associated with a modest impact on treatment adherence. Purpose. To assess the impact of the COVID-19 pandemic on adherence to oral endocrine therapy in patients diagnosed with breast cancer in the public healthcare system in Catalonia (Spain). Methods. Retrospective cohort study in patients starting endocrine therapy from 2017 to 2021. Adherence was measured during the first year of treatment, and the impact of the pandemic was calculated according to the calendar year and whether the first year of treatment included the peak period of the pandemic in our setting (March–September 2020). Analyses were performed using a chi-square test and multivariable logistic regression, with results stratified by year, age group, and drug type. Results. Mean overall adherence during the first year of treatment was 89.6% from 2017 to 2021. In contrast, the patients who started treatment in 2019 and 2020 and whose treatment included the peak pandemic period presented an adherence of 87.0% and 86.5%, respectively. Young age and tamoxifen or combination therapy were predictors of low adherence. An increase in neoadjuvant therapy was also observed in 2020. Conclusions. The COVID-19 pandemic had only a modest impact on adherence to endocrine therapy (≈3%), despite the enormous disruptions for patients, the healthcare system in general, and cancer care in particular that were occurring in that period. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF